Rapport Therapeutics (RAPP) Change in Accured Expenses (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 1154.68% year-over-year to -$3.5 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 349.9% increase from a year earlier, with the FY2025 full-year figure at $6.2 million, up 1561.99% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.5 million, down from $3.7 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for RAPP reached as high as $3.7 million in Q4 2025 and fell as low as -$3.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged $684363.6 across 4 years, with a median of $453000.0 in 2025.
• Across the five-year window, Change in Accured Expenses soared 433.33% in 2025 and slumped 1154.68% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $3.4 million in 2023, then tumbled by 74.89% to $848000.0 in 2024, then soared by 334.67% to $3.7 million in 2025, then sank by 194.71% to -$3.5 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.5 million in Q1 2026, $3.7 million in Q4 2025, and $1.7 million in Q3 2025.